Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Arthritis Advisory Committee votes against approval of Novartis' biologic for treatment of gout attacks, citing the need for more data on long-term safety and retreatment, along with a narrower indication.
You may also be interested in...
Approval of the leishmaniasis treatment by its December user fee date would give the Canadian sponsor a voucher for a priority review, which it is likely to sell to another company.
FDA’s decision not to approve rilonacept for preventing gout flares was unsurprising, given its Arthritis Advisory Committee’s unanimous recommendation against the indication. Regeneron says FDA’s letter requests “additional clinical data,” as well as chemistry, manufacturing and controls information.
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.